GlassScriptPhysician profile
John D Fallon
NPI 1265655252
$2,017.15
in general payments reported to CMS, 2019-2025
17 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $457 · 2023: $611 · 2024: $386 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $476.57 | 2021-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $457.68 | 2021-2025 | Cuvitru, Eohilia |
| Abbvie INC. | $243.21 | 2023-2024 | |
| Lilly USA, LLC | $238.41 | 2021-2023 | Mounjaro |
| Pfizer INC. | $208.52 | 2023-2025 | |
| Grifols USA, LLC | $88.46 | 2022-2023 | Gamunex-C |
| Biohaven Pharmaceutical Holding Company LTD. | $58.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.11 | 2023 | Xifaxan, Trulance |
| Octapharma USA, INC. | $32.70 | 2023 | Panzyga |
| Teva Pharmaceuticals USA, INC. | $27.57 | 2022 | |
| Arbor Pharmaceuticals, INC. | $27.24 | 2021 | |
| Ferring Pharmaceuticals INC. | $20.42 | 2024 | Rebyota |
| Argenx US, INC. | $19.91 | 2025 | Vyvgart Hytrulo |
| Bio Products Laboratory USA, INC. | $17.61 | 2023 | Coagadex, Gammaplex |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.98 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.09 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.